Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 7.1% - Here's What Happened

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report)'s stock price was up 7.1% during trading on Monday . The stock traded as high as $2.21 and last traded at $2.20. Approximately 1,000,925 shares traded hands during trading, a decline of 36% from the average daily volume of 1,565,929 shares. The stock had previously closed at $2.05.

Wall Street Analyst Weigh In

AUTL has been the topic of a number of research reports. Truist Financial dropped their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, June 12th. Finally, Wells Fargo & Company dropped their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Price Performance

The company has a market cap of $604.14 million, a P/E ratio of -2.58 and a beta of 1.76. The company has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. On average, analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently made changes to their positions in the company. Jane Street Group LLC raised its holdings in shares of Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock valued at $159,000 after acquiring an additional 91,222 shares during the period. Armistice Capital LLC raised its stake in Autolus Therapeutics by 19.6% during the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock valued at $17,050,000 after purchasing an additional 1,800,000 shares during the period. Vident Advisory LLC acquired a new stake in Autolus Therapeutics during the 1st quarter valued at $241,000. Tema Etfs LLC acquired a new stake in Autolus Therapeutics during the 1st quarter valued at $171,000. Finally, Wellington Management Group LLP raised its stake in Autolus Therapeutics by 6.9% during the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock valued at $41,992,000 after purchasing an additional 1,746,020 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.